Compare Paychex, Inc. (PAYX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs 10X Genomics Inc — how do they compare? Paychex, Inc. trades at $111.32 (market cap $39.82B), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: Paychex, Inc. is far larger — about 7.3× 10X Genomics Inc's market cap, and Paychex, Inc. pays a 4.25% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| PAYX | TXG | |
|---|---|---|
Market Cap | $39.82B | $5.48B |
Sector | Industrials | Health |
52-Week High | $147.99 | $47.20 |
52-Week Low | $85.57 | $11.34 |
Enterprise Value | $43.31B | $5.02B |
Dividend Yield | 4.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $111.96, down 2.12% on the day, with technical indicators showing a bullish trend despite overbought RSI readings. The company maintains strong profitability with 27.03% net margins and has beaten earnings estimates for three consecutive quarters. Recent dividend declarations of $1.19 per share and positive small business job growth data support the investment case.
The outlook remains positive with steady revenue growth and AI expansion driving future earnings. Key risks include macroeconomic headwinds affecting small business hiring and elevated valuation multiples. Analyst consensus is mixed with a $110 price target slightly below current levels, suggesting cautious optimism amid strong fundamentals.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
